Anti-oestrogenic drugs and endometrial cancers

Toxicology Letters

Volumn 120, Issue 1-3, 2001, Pages 21-29

  White, Ian N H ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

DNA damage; Oestrogen receptor; Raloxifene; Tamoxifen; Toremifene; Uterine tumours

Indexed keywords

ANTIESTROGEN; CELL DNA; ESTROGEN RECEPTOR; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CELL DAMAGE; CELL PROLIFERATION; CONFERENCE PAPER; DRUG EFFECT; ENDOMETRIUM CANCER; GENOTOXICITY; HUMAN; LIVER CANCER; METASTASIS; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; UTERUS;

ANIMALS; DNA DAMAGE; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; RATS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 0035977884     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(01)00303-4     Document Type: Conference Paper

References (48)

1. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays
2. Alpha-hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: Identification and quantification in vivo and in vitro
3. Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of α-hydroxytamoxifen in vitro: A metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts
4. Lack of genotoxicity of tamoxifen in human endometrium
5. A lack of evidence for the genotoxicity of tamoxifen and toremifene in the human endometrium
6. An epigenetic mechanism for tamoxifen-associated uterine carcinogenesis?
7. Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: Promotion by phenobarbital
8. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: The relationship between cell proliferation and liver tumour formation
9. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse
10. Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia
11. Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol
12. The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial
13. Second cancers after adjuvant tamoxifen therapy for breast cancer
14. Morphologic endometrium changes with tamoxifen
15. Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen
16. Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats
17. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
18. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
19. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
20. Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats
21. Induction of covalent DNA adducts in rodents by tamoxifen
22. Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Cr1:CD(BR) rats
23. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients
24. Activation of transcription by estrogen receptor alpha and beta is cell type- and promoter-dependent
25. Antiestrogenic action of raloxifene and tamoxifen: Today and tomorrow
26. Insights from the study of animals lacking functional estrogen receptor
27. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus
28. Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus
29. Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen
30. Analysis of tamoxifen-DNA adducts in humans and rats by accelerator mass spectrometry
31. Uterine carcinoma in mice treated neonatally with tamoxifen
32. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth
33. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen
34. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
35. Cancer statistics, 1996
36. α-hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA binding activity in rat hepatocytes
37. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer
38. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism
39. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer
40. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies
41. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen
42. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: The effects of tamoxifen
43. Tamoxifen
44. Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57Bl/6 mice and in human MCL-5 cells
45. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved
46. 14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry
47. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene